The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer
Open accessAbstract
The dual-targeted immunogene therapy that inhibits PD-L1 and provides IL-2 can enhance the therapeutic efficacy of cancer vaccine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002 · cited 1×
“To overcome these challenges, nanoscale formulations were designed and used to encapsulate the therapeutic genetic cargoes with enhanced stability, controlled cargo release properties, and increased transfection activity (13, 14).”
BackgroundCancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
IL-2: The First Effective Immunotherapy for Human Cancer
Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,289
Salmon, H., Idoyaga, J., Rahman, A., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M., Agudo, J., Tung, N., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.03.012 · Cited by 1,201
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
Munn, D. H., & Mellor, A. L. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.002 · Cited by 1,041
TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression
Yang, L., Pang, Y., & Moses, H. L. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.04.002 · Cited by 1,023
Dendritic Cells and Cancer Immunity
Gardner, A., & Ruffell, B. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.09.006 · Cited by 907
Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy
Palmerston Mendes, L., Pan, J., & Torchilin, V. (2017) · Molecules · doi:10.3390/molecules22091401 · Cited by 701
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Huang, Y., Goel, S., Duda, D. G., Fukumura, D., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4354 · Cited by 669
Self-citationEvolving synergistic combinations of targeted immunotherapies to combat cancer
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Gracia, J. L. P., & Haanen, J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3973 · Cited by 637
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601
Carroll, E. C., Jin, L., Mori, A., Muñoz-Wolf, N., Oleszycka, E., Moran, H. B. T., Mansouri, S., McEntee, C. P., Lambe, E., Agger, E. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.004 · Cited by 596
The hallmarks of successful anticancer immunotherapy
Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., & López-Soto, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7807 · Cited by 575
Acquired resistance to immunotherapy and future challenges
Restifo, N. P., Smyth, M. J., & Snyder, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.2 · Cited by 467
Chen, Y., Ramjiawan, R. R., Reiberger, T., Ng, M. R., Hato, T., Huang, Y., Ochiai, H., Kitahara, S., Unan, E. C., Reddy, T. P., et al. (2015) · Hepatology · doi:10.1002/hep.27665 · Cited by 451
Self-citationLi, J., Yang, Y., & Huang, L. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.020 · Cited by 306
Dong, P., Xiong, Y., Yue, J., Hanley, S. J. B., & Watari, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00386 · Cited by 305
Laoui, D., Keirsse, J., Morias, Y., Van Overmeire, E., Geeraerts, X., Elkrim, Y., Kiss, M., Bolli, E., Lahmar, Q., Sichien, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms13720 · Cited by 277
Ramakrishna, G., Rastogi, A., Trehanpati, N., Sen, B., Khosla, R., & Sarin, S. K. (2013) · Liver Cancer · doi:10.1159/000343852 · Cited by 238
Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors
Miao, L., Liu, Q., Lin, C. M., Luo, C., Wang, Y., Liu, L., Yin, W., Hu, S., Kim, W. Y., & Huang, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0866 · Cited by 215
Self-citationImmunotherapy of autoimmunity and cancer: the penalty for success
Caspi, R. R. (2008) · Nature Reviews Immunology · doi:10.1038/nri2438 · Cited by 181
Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery
Lo, A., Lin, C.-T., & Wu, H.-C. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2359 · Cited by 179
Self-citationProspects of IL-2 in Cancer Immunotherapy
Choudhry, H., Helmi, N. M., Abdulaal, W. H., et al. (2018) · BioMed Research International · doi:10.1155/2018/9056173 · Cited by 146
Wang, S., Li, J., Xie, J., Liu, F., Duan, Y., Wu, Y., Huang, S., He, X., Wang, Z., & Wu, X. (2018) · Oncogene · doi:10.1038/s41388-018-0252-x · Cited by 124
An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis
Reiberger, T., Chen, Y., Ramjiawan, R. R., Hato, T., Fan, C., Samuel, R., Roberge, S., Huang, P., Lauwers, G. Y., Zhu, A. X., et al. (2015) · Nature Protocols · doi:10.1038/nprot.2015.080 · Cited by 121
Self-citationFocusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
Weigelin, B., Bolaños, E., Teijeira, Á., Martínez‐Forero, I., Labiano, S., Azpilikueta, A., Morales‐Kastresana, A., Quetglas, J. I., Wagena, E., Sánchez-Paulete, A. R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1506357112 · Cited by 118
The Role of Prostaglandin E 2 in Tumor-Associated Immunosuppression
Wang, D., & DuBois, R. N. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.11.003 · Cited by 114
Hao, C., Tian, J., Liu, H., Li, F., Niu, H., & Zhu, B. (2017) · Medicine · doi:10.1097/md.0000000000007325 · Cited by 108
Flynn, M. J., Sayed, A. A., Sharma, R., Siddique, A., & Pinato, D. J. (2018) · Hepatology · doi:10.1002/hep.30337 · Cited by 98
Local and transient gene expression primes the liver to resist cancer metastasis
Goodwin, T. J., Zhou, Y., Musetti, S., Liu, R., & Huang, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2306 · Cited by 80
Wen, L., Bing, X., Wu, P., Lin, C., Peng, C., Wang, G., Lee, J., Lu, L., & Feng, G. (2019) · Hepatology · doi:10.1002/hep.30528 · Cited by 66
Self-citationLiu, C., Chern, G., Hsu, F., Huang, K., Sung, Y., Huang, H., Qiu, J.-T. T., Wang, S., Lin, C., Wu, C., et al. (2017) · Hepatology · doi:10.1002/hep.29513 · Cited by 51
Self-citationYu, T.-W., Chueh, H.-Y., Tsai, C.-C., Lin, C.-T., & Qiu, J.-T. T. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1221551 · Cited by 43
Self-citationNext Generation Cancer Vaccines—Make It Personal!
Terbuch, A., & Lopez, J. S. (2018) · Vaccines · doi:10.3390/vaccines6030052 · Cited by 33
Lin, C.-C., Tsai, C.-C., Lee, J., Fang, C.-H., Chang, K.-S., Wong, K., Lin, C.-T., & Qiu, J.-T. T. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.106 · Cited by 16
Self-citationYan, J.-Y., Liu, C., Wu, Z.-W., Chien, C., Chiu, W., & Lin, S. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb01435b · Cited by 5
Self-citation
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Lu, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Canadas, I., Tian, Y., Niu, X., Wang, Y., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 373
Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery
Waheed, S., Li, Z., Zhang, F., Chiarini, A., Armato, U., & Wu, J. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01605-4 · Cited by 259
Yue, N.-N., Xu, H.-M., Xu, J., Zhu, M.-Z., Zhang, Y., Tian, C.-M., Nie, Y.-Q., Yao, J., Liang, Y.-J., Li, D.-F., et al. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s413141 · Cited by 46
Metadata
- Authors
- Huang, K.-W., Hsu, F.-F., Qiu, J. T., Chern, G.-J., Lee, Y.-A., Chang, C.-C., Huang, Y.-T., Sung, Y.-C., Chiang, C.-C., Huang, R.-L., Lin, C.-C., Dinh, T. K., Huang, H.-C., Shih, Y.-C., Alson, D., Lin, C.-Y., Lin, Y.-C., Chang, P.-C., Lin, S.-Y., & Chen, Y.
- Venue
- Science Advances
- Published
- 2020-01-17
- Volume
- 6
- Issue
- 3
- Pages
- eaax5032-eaax5032
- ISSN
- 2375-2548 (ISSN-L)
- OpenAlex
- W3000567428
- Cited by
- 256
- References
- 39
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.